Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 2/20 | 0.50 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.46 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.46 |
| ▸ | PRMT8 | Q9NR22 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | RAD52 | P43351 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | GNAI3 | P08754 | 4/20 | 0.38 |
| ▸ | GNAO1 | P09471 | 4/20 | 0.38 |
| ▸ | GNAI1 | P63096 | 4/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10877052 | 0.94 | CXCR4 (0.52) | CXCR4CARM1PRMT6PRMT8HSD17B10 | |
| SCHEMBL23598233 | 0.92 | CXCR4 (0.55) | CXCR4CARM1PRMT6PRMT8HSD17B10 | |
| SCHEMBL681608 | 0.86 | CARM1 (0.62) | CXCR4CARM1PRMT6PRMT8HSD17B10 | |
| SCHEMBL29699560 | 0.84 | — | — | |
| SCHEMBL8403611 | 0.84 | CARM1 (0.56) | CARM1PRMT6PRMT8SMN1; SMN2PRMT1 | |
| SCHEMBL15065607 | 0.82 | CXCR4 (0.54) | CXCR4HSD17B10SIGMAR1RAD52POLB | |
| SCHEMBL25030266 | 0.81 | TSHR (0.41) | CXCR4CARM1PRMT6PRMT8PRMT1 | |
| SCHEMBL7466414 | 0.81 | CXCR4 (0.39) | CXCR4CARM1PRMT6PRMT8HSD17B10 | |
| SCHEMBL22124827 | 0.80 | MEN1 (0.43) | CXCR4CARM1PRMT6PRMT8HSD17B10 | |
| SCHEMBL13867477 | 0.79 | CARM1 (0.73) | CARM1PRMT6PRMT8SMN1; SMN2PRMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9856216-B2 | Compounds as TNIK, IKKε and TBK1 inhibitors and pharmaceutical composition comprising same | GREEN CROSS CORPORATION (KR) | 2018-01-02 | — | — | US | claimed |
| US-20160311772-A1 | COMPOUNDS AS TNIK, IKKEPSILON AND TBK1 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2016-10-27 | — | — | US | claimed |
| US-20130123344-A1 | METHOD OF PREVENTING OR TREATING VIRAL INFECTION | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2013-05-16 | — | — | US | claimed |
| US-20110009512-A1 | REDUCTION OF ALDEHYDES IN AMINES | HUNTSMAN PETROCHEMICAL LLC (US) | 2011-01-13 | — | — | US | claimed |
| EP-2257592-A2 | REDUCTION OF ALDEHYDES IN AMINES | Huntsman Petrochemical LLC (US) | 2010-12-08 | — | — | EP | claimed |
| WO-2009117479-A2 | REDUCTION OF ALDEHYDES IN AMINES | HUNTSMAN PETROCHEMICAL CORPORATION (US) | 2009-09-24 | — | — | WO | claimed |
| EP-1490367-B1 | IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2008-07-23 | — | — | EP | claimed |
| US-7348339-B2 | 2-(4-amino-furazan-3-yl)-1-ethyl-N-[(2R)-2-morpholinylmethyl]-1H-imidazo[4,5-c]pyridine-7-carboxamide; Mitogen- and Stress-Activated Protein (MSK) and Rho (guanosine triphosphate) 1 or 2 kinase inhibitor; neurodegenerative diaeases; antiinflammatory, anticarcinogenic, antiviral and antibacterial agent | GLAXO GROUP LIMITED (GB) | 2008-03-25 | — | — | US | claimed |
| US-7060700-B2 | Amide derivatives useful as inhibitors of the production of cytokines | ASTRAZENECA AB (SE) | 2006-06-13 | — | — | US | claimed |
| US-20050197328-A1 | Imidazopyridine derivatives as kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2005-09-08 | — | — | US | claimed |
| WO-2003080610-A1 | IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-10-02 | — | — | WO | claimed |
| US-20030105142-A1 | Amide derivatives useful as inhibitors of the production of cytokines | ASTRAZENECA AB | 2003-06-05 | — | — | US | claimed |
| US-6432949-B1 | Amide derivatives useful as inhibitors of the production of cytokines | ASTRAZENECA AB (SE) | 2002-08-13 | — | — | US | claimed |
| EP-1102750-A1 | AMIDE DERIVATIVES USEFUL AS INHIBITORS OF THE PRODUCTION OF CYTOKINES | AstraZeneca AB (SE) | 2001-05-30 | — | — | EP | claimed |
| WO-2000007991-A1 | AMIDE DERIVATIVES USEFUL AS INHIBITORS OF THE PRODUCTION OF CYTOKINES | ASTRAZENECA AB (SE) | 2000-02-17 | — | — | WO | claimed |
| WO-1998039399-A1 | ASHLESS FRICTION MODIFIER WITH VISCOSITY INDEX IMPROVING CREDIT AND LUBRICATING OIL COMPOSITION CONTAINING SAME | UNIROYAL CHEMICAL COMPANY, INC. (US) | 1998-09-11 | — | — | WO | claimed |
| US-5721200-A | REACTING OLEFINIC COPLYMER WITH UNSATURATED ACYLATING AGENT TO FROM A GRAFT COPOLYMER AND REDUCING MOLECULAR WEIGHT, REACTING GRAFTED COPOLYMER WITH AMINO-ALCOHOL COMPOUND | DSM COPOLYMER, INC. (US) | 1998-02-24 | — | — | US | claimed |
| US-5474694-A | Dispersant additive which is an modified alpha-olefin polymer | TEXACO INC. (US) | 1995-12-12 | — | — | US | claimed |
| EP-0515152-A1 | Dispersant additive and lubricating oil composition containing same | TEXACO DEVELOPMENT CORPORATION (US) | 1992-11-25 | — | — | EP | claimed |
| US-5162086-A | Amino-phenothiazine modified graft polymer | TEXACO INC. (US) | 1992-11-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311772-A1 | COMPOUNDS AS TNIK, IKKEPSILON AND TBK1 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | TNIK, TNK1, NFKBIA | CXCR4 4258/4885CARM1 3467/4885PRMT6 4050/4885 |
| US-20130123344-A1 | METHOD OF PREVENTING OR TREATING VIRAL INFECTION | KDM1B, KDM1A, KDM2A | CXCR4 3034/4885CARM1 44/4885PRMT6 50/4885 |
| US-20050197328-A1 | Imidazopyridine derivatives as kinase inhibitors | NR4A3, XDH, MAPK8 | CXCR4 124/4885CARM1 527/4885PRMT6 444/4885 |
| US-20030105142-A1 | Amide derivatives useful as inhibitors of the production of cytokines | IL6, IL6ST, IL2 | CXCR4 264/4885CARM1 3436/4885PRMT6 1007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.